Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Retinal degeneration

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    224 result(s) found for: Retinal degeneration. Displaying page 1 of 12.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-001571-37 Sponsor Protocol Number: AAV2/2-hRPE65p-hRPE65 Start Date*: 2006-12-14
    Sponsor Name:University College London
    Full Title: AN OPEN-LABEL DOSE ESCALATION STUDY OF AN ADENO-ASSOCIATED VIRUS VECTOR (AAV2/2-hRPE65p-hRPE65) FOR GENE THERAPY OF SEVERE EARLY-ONSET RETINAL DEGENERATION
    Medical condition: The condition to be investigated is severe early-onset inherited retinal degeneration due to defects in the gene encoding RPE65
    Disease: Version SOC Term Classification Code Term Level
    13.1 10015919 - Eye disorders 10038845 Retinal degeneration PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-021777-37 Sponsor Protocol Number: Lucentis-LucERG Start Date*: 2010-09-27
    Sponsor Name:Universitätsklinikum Schleswig-Holstein (UK-SH)
    Full Title: "A prospective, non-randomized, mono-center, cohort study to evaluate the short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with we...
    Medical condition: Retinal function in patients with wet age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004367-57 Sponsor Protocol Number: Start Date*: 2008-05-14
    Sponsor Name:Department of Ophthalmology, Medical University of Graz
    Full Title: Treatment of retinal angiomatous proliferation lesions due to age-related macular degeneration with ranibizumab (Lucentis®) and photodynamic therapy with verteporfin (Visudyne®)
    Medical condition: Subtype of neovascular age-related macular degeneration, so called retinal angiomatous proliferation or RAP.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10015902 Exudative senile macular degeneration of retina LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000379-41 Sponsor Protocol Number: RLBUHT3407 Start Date*: 2007-05-22
    Sponsor Name:Royal Liverpool & Broadgreen University hospital
    Full Title: Liverpool Avastin Dose Response and Retreatment Study
    Medical condition: Exudative senile macular degeneration of the retina
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015902 Exudative senile macular degeneration of retina LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-004675-22 Sponsor Protocol Number: ADM-PED08 Start Date*: 2008-10-21
    Sponsor Name:University of Bonn
    Full Title: Intravitreal ranibizumab in patients with retinal pigment epithelial detachments secondary to AMD
    Medical condition: Pigment epithelial detachments secondary to age-relatedmacular degeneration
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064930 Age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000765-20 Sponsor Protocol Number: ANTIVEGFVEP Start Date*: 2015-11-27
    Sponsor Name:Kuopion yliopistollinen sairaala/silmätautien poliklinikka
    Full Title: The Effect of Intravitreal Bevacizumab Injections in Patients with Macular Oedema Caused by AMD, CRVO or DME on the Plasticity of Nerves Studied by Visual Evoked Potentials
    Medical condition: Wet age-related macular degeneration, diabetic macular edema, central retinal vein occlusion
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004853 10012675 Diabetic macular retinopathy LLT
    18.1 100000004853 10007972 Central retinal vein occlusion LLT
    18.1 100000004853 10015902 Exudative senile macular degeneration of retina LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016158-42 Sponsor Protocol Number: IT-04-1-8-09 Start Date*: 2009-12-23
    Sponsor Name:U.L.S.S. 16
    Full Title: Efficacy of intravitreal bevacizumab for exudative age-related macular degeneration.
    Medical condition: Exudative age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    12.1 10015902 Exudative senile macular degeneration of retina LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-006290-90 Sponsor Protocol Number: AU-06102G Start Date*: 2008-10-10
    Sponsor Name:Society (Institute) for clinical research
    Full Title: Subretinal Macugen for neovascular age-related macular degeneration (SUMANA)
    Medical condition: Neovascular (exudative) age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015902 Exudative senile macular degeneration of retina LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005290-30 Sponsor Protocol Number: TCA-05-01 Start Date*: 2006-10-18
    Sponsor Name:Department of Ophthalmology, Semmelweis University
    Full Title: A Non- randomized, Single-Center, Open Label Case Series Study of Intravitreal Triamcinolone Acetate Injections (IVTA) Used as Adjunctive to Verteporfin Photodynamic Therapy (PDT) in the Treatment ...
    Medical condition: Age- related macular degeneration with predominantly classic subfoveal choroidal neovascularisation
    Disease: Version SOC Term Classification Code Term Level
    8.1 10015902 Exudative senile macular degeneration of retina LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002168-34 Sponsor Protocol Number: FNB-OK-2013-01 Start Date*: 2014-12-09
    Sponsor Name:Doc. MUDr. Petr Kolář, PhD, Oční klinika FN Brno
    Full Title: Study To Determine Efficacy of Aflibercept For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration
    Medical condition: Retinal angiomatous proliferation secondary to wet age related macular degeneration.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10064930 Age-related macular degeneration PT
    17.0 10015919 - Eye disorders 10069125 Retinal angiomatous proliferation LLT
    17.0 10015919 - Eye disorders 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-013062-11 Sponsor Protocol Number: AR-OCUL-1 Start Date*: 2007-03-29
    Sponsor Name:AZIENDA USL 8 AREZZO
    Full Title: BEVACIZUMAB COMBINED WITH PDT, VERSUS RANIBIZUMAB AND PEGAPTANIB BOTH COMBINED WITH PDT FOR NEOVACULAR AGE RELATED MACULAR DEGENERATION CLINICAL TRIAL
    Medical condition: Neovascular Age Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015902 Exudative senile macular degeneration of retina LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001281-33 Sponsor Protocol Number: RGHT000449 Start Date*: 2007-07-09
    Sponsor Name:Belfast Health and Social Care Trust [...]
    1. Belfast Health and Social Care Trust
    2. Queen's University Belfast, Research and Regional Services
    Full Title: A randomised control trial of alternative treatments to Inhibit VEGf in Age-related choroidal Neovascularisation(IVAN)
    Medical condition: Choroidal neovascularisation in age related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10015902 Exudative senile macular degeneration of retina LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-021968-15 Sponsor Protocol Number: ID_2909 Start Date*: 2010-08-06
    Sponsor Name:AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA
    Full Title: NOT RANDOMISED OPEN LABEL STUDY TO COMPARE EFFICACY OF BEVACIZUMAB (AVASTIN, ROCHE) VERSUS RANIBIZUMAB (LUCENTIS, NOVARTIS) ADMINISTERED BY INTRAVITREAL INJECTION IN PATIENTS WITH EXUDATIVE AGE REL...
    Medical condition: exudative age related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015902 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-016926-15 Sponsor Protocol Number: OFT-09-01 Start Date*: 2010-03-11
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Intravitreal Bevacizumab associated with epiretinal brachitherapy as a treatment for Coroidal Neovascularization (CNV) secondary to exudative Age Related Macular Degeneration (AMD)
    Medical condition: exudative Age Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    12.1 10015902 Exudative senile macular degeneration of retina LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004567-30 Sponsor Protocol Number: 1313.20 Start Date*: 2014-04-15
    Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG
    Full Title: A single arm open label study to evaluate the pharmacodynamics and safety of a 4 wk treatment with BI 144807 in patients with newly diagnosed wet age related macular degeneration (wAMD)
    Medical condition: patients with newly diagnosed, unilateral, wet Are-Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004853 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002202-70 Sponsor Protocol Number: Start Date*: 2011-09-22
    Sponsor Name:Universitätsklinikum Schleswig-Holstein (UK-SH)
    Full Title: A prospective, non-randomized, mono-center, cohort study to evaluate the effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with diabetic macular edema (...
    Medical condition: Retinal function in patients with wet age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003766-17 Sponsor Protocol Number: 2007-06 Start Date*: 2007-12-06
    Sponsor Name:The Eye Hospital Rotterdam
    Full Title: Avastin-Injections in Age Related Macular Degeneration: Prospective Study for Optimal Frequency and Follow-up Determination
    Medical condition: Age-Related Macular Degeneration (ARMD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064930 Age-related macular degeneration LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-002101-39 Sponsor Protocol Number: MD7111396 Start Date*: 2008-09-25
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: An extension study to protocol MD7108240; pazopanib eye drops in subjects with neovascolar age-related macular degeneration
    Medical condition: Neovascular age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025409 Macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001961-20 Sponsor Protocol Number: FYB201-C2015-01-P3 Start Date*: 2015-11-24
    Sponsor Name:Bioeq GmbH
    Full Title: Efficacy and safety of the biosimilar ranibizumab FYB201 in comparison to Lucentis in patients with neovascular age-related macular degeneration (COLUMBUS-AMD)
    Medical condition: Subfoveal neovascular age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    20.0 100000116602 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) AT (Completed) DE (Completed) HU (Completed) ES (Completed) FR (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002526-43 Sponsor Protocol Number: 150998-001 Start Date*: 2012-01-30
    Sponsor Name:Allergan Limited
    Full Title: Single and Repeat Dose Study of the Safety and Efficacy of AGN-150998 in Patients with Exudative Age-related Macular Degeneration
    Medical condition: Exudative Age-related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10025411 Macular degeneration senile LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 06:39:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA